Trump considering Dr. Scott Gottlieb to 長，率いる U.S. FDA
By Toni Clarke
Dec 12 (Reuters) - Dr. Scott Gottlieb, a partner at one of the world's largest 投機・賭ける 資本／首都 基金s and a former 副 commissioner at the U.S. Food and 麻薬 行政, is 存在 considered by 大統領-elect Donald Trump to run the 機関, によれば sources の近くに to the 移行 team.
Gottlieb, 44, a 投機・賭ける partner at New 企業 Associates and 居住（者） fellow at the American 企業 学校／設ける, a 保守的な think 戦車／タンク based in Washington, is 井戸／弁護士席 known in health 政策 circles and is a たびたび（訪れる） commentator on television and in print.
Gottlieb is 存在 considered と一緒に Jim O'Neill, a self-宣言するd libertarian and 同僚 of Peter Thiel, the co-創立者 of Mithril 資本／首都 管理／経営 who was an 早期に Trump 支持者 and is now advising his 移行 team. Bloomberg News first 報告（する）／憶測d that Trump was looking at O'Neill.
Trump, a 共和国の／共和党の, takes office on Jan. 20.
Michael Gaba, 連邦の 政策 leader of 法律 会社／堅い Holland & Knight's 国家の Healthcare & Life Sciences Team, said Gottlieb would be more palatable to more people than O'Neill, who believes 麻薬s should be 許すd on the market before their efficacy has been 設立するd, as long as they are 安全な.
Even the 麻薬 産業 would likely …に反対する that 姿勢, Gaba said, since companies want to be able to make 信頼できる （人命などを）奪う，主張するs that their 製品s are 効果的な in 扱う／治療するing the 病気s they say do.
"They want the FDA's Good Housekeeping 調印（する） of 是認," Gaba said last week, 追加するing, however, that 麻薬 製造者s would like to 供給する いっそう少なく data to get it.
Gottlieb would be a more 伝統的な choice than O'Neill and fits the profile of what Trump's 行政 seems to be looking for, he said.
"He leans 権利, he's got experience in the 機関, he's got the M.D. credential, and he's outspoken," Gaba said.
The FDA 歴史的に has 指名するd someone with 医療の 信任状 to 長，率いる the 機関. O'Neill has 非，不，無, though he served as 主要な／長／主犯 associate 副 長官 of health and human services under the George W. Bush 行政.
Gottlieb's 関係 to the 製薬の 産業 run 深い. He sits on the boards of 多重の companies and advises others, 含むing the British 製薬の 巨大（な） GlaxoSmithKline Plc .
He is also a managing director of 投資 banking at T.R. Winston & Co, a Los Angeles-based, 個人として held 投資 bank that 焦点（を合わせる）s on healthcare, clean energy and 消費者 科学（工学）技術.
によれば its website, the 会社／堅い 供給するs services to a 範囲 of healthcare （弁護士の）依頼人s, "含むing companies engaged in the 臨床の 開発 of new 治療力のある 構内／化合物s, 麻薬 発見 techniques, 医療の 科学（工学）技術s, and 装置s."
Between 2003 and 2004 Gottlieb was a 上級の 助言者 to the FDA commissioner and then the 機関's director of 医療の 政策 開発. In 2004 he also 行為／法令／行動するd as 上級の 助言者 to the 中心s for Medicare and Medicaid Services.
From 2005-2007 he was the FDA's 副 commissioner for 医療の and 科学の 事件／事情／状勢s.
Gottlieb has a 医療の degree from 開始する Sinai School of M edicine and a bachelor's degree in 経済的なs from Wesleyan University. He advises the U.S. Department of Health and Human Services as a member of the 連邦の Health （警察などへの）密告，告訴（状） 科学（工学）技術 政策 委員会. (報告（する）／憶測ing by Toni Clarke in Washington; Editing by Jonathan Oatis)
